Business Wire

Arthur D. Little: New Report Offers a Blueprint for Overcoming Bottlenecks and Unlocking the Full Potential of Digitalisation in the Chemical Industry

19.4.2023 10:51:00 EEST | Business Wire | Press release

Share

Digitalisation has the power to transform the European chemical industry, revolutionising the sector's solutions and enabling a circular, more sustainable economy in line with the EU Green Deal objectives. This exciting potential is highlighted in a new report from Arthur D. Little and Cefic, the European Chemical Industry Council, which details how technologies like artificial intelligence, big data, Internet of Things, digital twins, robotics, virtual/augmented reality, and blockchain can accelerate the industry's transformation.

The study titled "Digital Technologies for Sustainability in the European Chemical Industry", is the first ever attempt to outline how these technologies are used in the chemical sector and how they can be scaled up to make the chemical industry’s processes and products more sustainable .

Dr. Daniel Witthaut, Executive Director for Innovation at Cefic, emphasises that while the EU chemical industry has already implemented digitalisation in various applications, there is still much more that can be done:

“Digitalisation in the chemical industry is not new with multiple players already applying digital technologies in their fields. However, enormous opportunities exist for the industry to reach their sustainability goals faster through the application of the latest digital technologies – a journey that is just beginning for most players. And this is where we also need to work more closely with EU institutions to remove existing bottlenecks, improve data sharing and create a larger pool of homegrown talent to implement all these new technologies”.

According to the research, digital technologies can make the greatest contribution in five priority areas in both large and small companies in the EU: (1) process design and production for climate and circularity objectives, (2) sustainability assessment, (3) enabling materials and chemicals circularity through tracking and tracing, (4) sustainable product design, and (5) safe and efficient logistics and distribution.

Dr. Michaël Kolk, Managing Partner at ADL, adds: “Chemical companies in Europe are not only working on their own sustainability objectives, but also providing solutions that serve as enablers for many downstream industries to reach their own. The picture is complex, but we believe that collaboration via greater digitalisation is the way forward.”

The report also highlights a number of challenges that must be addressed to fully realise the potential of digital technologies. These include technological challenges such as data availability, interoperability, standardisation and cybersecurity as well as reluctance among companies to share data, financial costs, organisational issues, and a shortage of digital skills in the workforce. Greater collaboration between EU institutions and the chemical industry will be needed to address some of these bottlenecks.

The report is available for download here: https://tinyurl.com/2s4bztsb

END

About the report

Arthur D. Little and the European Chemical Industry Council (Cefic) joined forces to prepare this report, which summarises the views of digital technology experts from within and outside the chemical industry.

Recommendations from this report are based on the result of 15 individual interviews with senior digital and sustainability experts (e.g., chief digital officers or chief sustainability officers) as well as a survey of more than 70 experts from 50 companies that are broad representatives of the chemical industry in terms of type of business, size, and region.

To add cross-industry perspectives, the study also took into account input from more than 10 globally recognised digital technology experts outside the chemical industry.

About Cefic

Cefic, the European Chemical Industry Council, founded in 1972, is the voice of large, medium and small chemical companies across Europe, which provide 1.2 million jobs and account for approximately about 15% of world chemicals production.

About Arthur D. Little

Arthur D. Little has been at the forefront of innovation since 1886. We are an acknowledged thought leader in linking strategy, innovation and transformation in technology-intensive and converging industries. We navigate our clients through changing business ecosystems to uncover new growth opportunities. We enable our clients to build innovation capabilities and transform their organizations.

Our consultants have strong practical industry experience combined with excellent knowledge of key trends and dynamics. ADL is present in the most important business centers around the world. We are proud to serve most of the Fortune 1000 companies, in addition to other leading firms and public sector organizations.

For further information, please visit www.adlittle.com or www.adl.com.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact: Marina Mendes
Cefic
+32 499239522
mam@cefic.be

Media contact: Sue Glanville
Catalyst Comms
+44 7715 817589
Glanville.sue@adlittle.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Galderma Receives U.S. FDA Approval for Differin ® Epiduo ® Acne Gel Prescription-to-OTC Switch22.5.2026 19:25:00 EEST | Press release

Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) use in ages 12 years and older, marking a significant Prescription-to-OTC transition in acne care. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522074280/en/ The U.S. FDA approves Differin® Epiduo® Acne Gel Prescription-to-OTC switch This milestone represents yet another example of Galderma’s unique Integrated Dermatology strategy, demonstrating how proven innovations from its Therapeutic Dermatology portfolio can further strengthen its Dermatological Skincare offerings. The Prescription‑to‑OTC transition highlights Galderma’s scale and expertise in successfully commercializing dermatology innovations across the full spectrum of acne care. With the appro

Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 17:18:00 EEST | Press release

Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522186975/en/ Adam Plich, CEO and Co-Founder of Avanzanite Bioscience. “Thalassaemia is a complex, chronic and multisystem disease characterised by anaemia, ineffective erythropoiesis and haemo

ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 15:30:00 EEST | Press release

OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future

Enhertu ® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority

Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 14:45:00 EEST | Press release

Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, signalling a shift in health systems from late-stage treatment to earlier intervention. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260522587414/en/ Selected from 393 submissions across 68 countries, the winning teams were recognised through the inaugural ‘Future Health Challenge 2026: Building Anticipatory Health Systems through Population Sensing’, delivered by Future Health – A Global Initiative by Abu Dhabi in collaboration with MIT Solve. Health systems globally are facing rising costs and persistent delays in diagnosis, with many conditions still identified only after symptoms become severe. At the sam

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye